Mancini Anthony sold $347K of RVMD

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

The European Medicines Agency's CHMP recommended six medicines, including Revolution Medicines' Rasonque, for approval. Rasonque targets metastatic pancreatic cancer and was prioritized under EMA's Cancer Medicines Pathfinder project.

Guggenheim maintained a Buy rating and $275 price target on Revolution Medicines (NASDAQ:RVMD) after the European Medicines Agency recommended approval of its drug Rasonque. The stock has risen 281% in the past year, though some analysts suggest it may be overvalued. Multiple firms have recently initiated coverage with positive ratings and price targets ranging from $226 to $318.

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

William Blair initiated coverage on Revolution Medicines (RVMD) with an Outperform rating and a $226 price target. The stock has gained 281% over the past year. The FDA approved Rasonque (daraxonrasib) for pancreatic cancer, with trials showing improved survival rates. Analysts cite strong early launch trends and commercial potential, though some note overvaluation. Multiple firms raised price targets following the approval.

Revolution Medicines (RVMD) announced the EMA's Committee for Medicinal Products for Human Use issued a positive opinion for RASONQUE as a monotherapy for adult patients with metastatic pancreatic adenocarcinoma. The recommendation is based on Phase 3 trial results showing RASONQUE improved overall survival (13.2 months vs. 6.7 months with chemotherapy) and progression-free survival (7.2 months vs. 3.6 months). The EMA's expedited review process was used.